EPS for ObsEva SA (OBSV) Expected At $-0.42; Waters Parkerson & Company Decreased Its Abbott Laboratories (ABT) Position

April 16, 2018 - By Hazel Jackson

Abbott Laboratories (NYSE:ABT) Logo

Waters Parkerson & Company decreased Abbott Laboratories (ABT) stake by 1.02% reported in 2017Q4 SEC filing. Waters Parkerson & Company sold 5,357 shares as Abbott Laboratories (ABT)’s stock rose 5.88%. The Waters Parkerson & Company holds 521,550 shares with $29.77 million value, down from 526,907 last quarter. Abbott Laboratories now has $103.55 billion valuation. The stock increased 1.38% or $0.805 during the last trading session, reaching $59.295. About 3.82 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 16, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Analysts expect ObsEva SA (NASDAQ:OBSV) to report $-0.42 EPS on May, 17.They anticipate $0.16 EPS change or 27.59% from last quarter’s $-0.58 EPS. After having $-0.48 EPS previously, ObsEva SA’s analysts see -12.50% EPS growth. The stock decreased 1.55% or $0.2 during the last trading session, reaching $13.03. About 7,957 shares traded. ObsEva SA (NASDAQ:OBSV) has risen 20.97% since April 16, 2017 and is uptrending. It has outperformed by 9.42% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on April, 18. They expect $0.58 EPS, up 20.83% or $0.10 from last year’s $0.48 per share. ABT’s profit will be $1.01 billion for 25.56 P/E if the $0.58 EPS becomes a reality. After $0.74 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts -21.62% negative EPS growth.

Investors sentiment increased to 0.91 in 2017 Q4. Its up 0.04, from 0.87 in 2017Q3. It increased, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Rnc Capital Mngmt Lc holds 17,357 shares or 0.07% of its portfolio. Parsec Finance Mgmt Inc reported 256,694 shares. Northwestern Mutual Wealth Management has 131,162 shares for 0.05% of their portfolio. Colonial Tru Advisors has 10,944 shares for 0.1% of their portfolio. Amundi Pioneer Asset Management accumulated 1.16M shares. M&R Capital Mngmt, New York-based fund reported 23,587 shares. L And S Advsr Inc reported 0.19% of its portfolio in Abbott Laboratories (NYSE:ABT). Pinnacle Prtn Inc invested in 0.28% or 46,858 shares. Summit Secs Llc stated it has 2.2% of its portfolio in Abbott Laboratories (NYSE:ABT). Bluefin Trading reported 0.39% of its portfolio in Abbott Laboratories (NYSE:ABT). Washington Tru Bancshares invested in 20,017 shares or 0.17% of the stock. 15,895 are owned by Impax Asset Mngmt Ltd Liability. 29,357 were accumulated by Essex Financial Service Incorporated. Nelson Roberts Advsrs Ltd Limited Liability Company holds 0.13% of its portfolio in Abbott Laboratories (NYSE:ABT) for 7,443 shares. Brown Advisory Secs Ltd Liability Corporation stated it has 0.61% in Abbott Laboratories (NYSE:ABT).

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, September 28 the stock rating was downgraded by Northland Capital to “Hold”. BMO Capital Markets maintained the stock with “Hold” rating in Thursday, July 20 report. Argus Research maintained Abbott Laboratories (NYSE:ABT) on Friday, July 21 with “Buy” rating. Cowen & Co maintained Abbott Laboratories (NYSE:ABT) rating on Friday, September 22. Cowen & Co has “Buy” rating and $55.0 target. The rating was maintained by Citigroup on Thursday, October 19 with “Neutral”. BTIG Research maintained the shares of ABT in report on Saturday, August 29 with “Buy” rating. Barclays Capital maintained the stock with “Overweight” rating in Thursday, January 25 report. The rating was downgraded by William Blair to “Market Perform” on Friday, January 29. The firm earned “Outperform” rating on Thursday, July 23 by RBC Capital Markets. The company was maintained on Friday, January 29 by RBC Capital Markets.

Since October 23, 2017, it had 1 buy, and 19 sales for $28.95 million activity. Bracken Sharon J also sold $62,056 worth of Abbott Laboratories (NYSE:ABT) shares. Fussell Stephen R also sold $3.36M worth of Abbott Laboratories (NYSE:ABT) on Friday, February 16. 27,733 Abbott Laboratories (NYSE:ABT) shares with value of $1.73 million were sold by Blaser Brian J. 905 Abbott Laboratories (NYSE:ABT) shares with value of $53,369 were sold by Salvadori Daniel Gesua Sive. MANNING JOSEPH J sold 1,430 shares worth $84,344. On Wednesday, March 7 Watkin Jared sold $183,579 worth of Abbott Laboratories (NYSE:ABT) or 3,000 shares. Shares for $96,728 were sold by BIRD ROGER on Wednesday, February 28.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>